Foundation News

Legislation will give patients and their doctors a process to seek exception to Step Therapy requirements that may delay necessary care.

The Crohn's & Colitis Foundation advocates for reform in the Pharmacy Benefit Manager (PBM) industry due to the negative impact it has on patients' access to medicine.

Last week, in an unprecedented decision, a Texas federal judge invalidated the Food and Drug Administration’s (FDA) approval of a drug that was approved by the agency in 2000.

April 3, 2023, New York, NY – Last week, the U.S. Equal Employment Opportunity Commission (EEOC) sued Walmart for firing a North Carolina employee with Crohn’s disease after the company allegedly refused to grant her disability-related leave.

Since 2017, IBD Ventures Has Invested Over $9 Million In R&D Funding to Portfolio Companies

New York, NY, March 14, 2023 – Early life stress (ELS) in mice can disrupt the gut immune response, leading to longer-lasting intestinal inflammation and a worsened future disease state than control mice not exposed to ELS, according to a new study published in Inflammatory B

NEW YORK, NY – The Crohn’s & Colitis Foundation announced today

For this year’s World Inflammatory Bowel Disease (IBD) day on May 19th, Veterans have a new way to receive support.

NEW YORK, NY – Dietary supplementation of pomegranate extract decreased disease severity and lowered inflammation in mice with colitis, according to a new study published in Molecular Nutrition and Food Research and

Prometheus Laboratories recently announced the launch of PredictrPK IFX, which uses a machine learning algorithm to combine patient weight, current dose and interval, measured serum IFX, measured antibodies-to-infliximab and albumin levels to predict optimal, individualized infliximab dosing.